Risk-reducing mastectomy and breast cancer mortality in women with a BRCA1 or BRCA2 pathogenic variant: an international analysis
Background Risk-reducing mastectomy (RRM) is offered to women with a BRCA1 or BRCA2 pathogenic variant, however, there are limited data on the impact on breast cancer mortality. Methods Participants were identified from a registry of women with BRCA1/2 pathogenic variants. We used a pseudo-randomise...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2024-02, Vol.130 (2), p.269-274 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Risk-reducing mastectomy (RRM) is offered to women with a
BRCA1
or
BRCA2
pathogenic variant, however, there are limited data on the impact on breast cancer mortality.
Methods
Participants were identified from a registry of women with
BRCA1/2
pathogenic variants. We used a pseudo-randomised trial design and matched one woman with a RRM to one woman without a RRM on year of birth, gene, and country. We estimated the hazard ratio (HR) and 95% confidence intervals (CI) for dying of breast cancer in the follow-up period.
Results
There were 1654 women included; 827 assigned to the RRM arm and 827 assigned to the control arm. After a mean follow-up of 6.3 years, there were 20 incident breast cancers (including 15 occult cancers) and two breast cancer deaths in the RRM arm, and 100 incident breast cancers and 7 breast cancer deaths in the control arm (HR = 0.26; 95% CI 0.05–1.35;
p
= 0.11). The probability of dying of breast cancer within 15 years after RRM was 0.95%.
Conclusions
In women with a
BRCA1
or
BRCA2
pathogenic variant, RRM reduces the risk of breast cancer, and the probability of dying of breast cancer is low. |
---|---|
ISSN: | 0007-0920 1532-1827 1532-1827 |
DOI: | 10.1038/s41416-023-02503-8 |